Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600014 | 1.00 | SCN9A (0.34) | SCN9AHTR1AHTR2BSIGMAR1CYP19A1 | |
| SCHEMBL3608207 | 0.94 | MTNR1A (0.35) | HTR1AHTR2BSIGMAR1CYP19A1MTNR1A | |
| SCHEMBL3608211 | 0.94 | MTNR1A (0.35) | HTR1AHTR2BSIGMAR1CYP19A1MTNR1A | |
| SCHEMBL3607373 | 0.91 | SCN9A (0.33) | SCN9AHTR1AHTR2BSIGMAR1MTNR1A | |
| SCHEMBL3607375 | 0.91 | SCN9A (0.33) | SCN9AHTR1AHTR2BSIGMAR1MTNR1A | |
| SCHEMBL3606361 | 0.90 | HTR1A (0.35) | HTR1AHTR2BSIGMAR1CYP19A1MTNR1A | |
| SCHEMBL29417401 | 0.90 | HTR1A (0.35) | HTR1AHTR2BSIGMAR1CYP19A1MTNR1A | |
| SCHEMBL3609514 | 0.90 | HTR1A (0.35) | HTR1AHTR2BSIGMAR1CYP19A1MTNR1A | |
| SCHEMBL3606365 | 0.90 | HTR1A (0.35) | HTR1AHTR2BSIGMAR1CYP19A1MTNR1A | |
| SCHEMBL2314363 | 0.88 | APP (0.38) | SCN9AHTR1AHTR2BSIGMAR1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | BOIZEL ROBERT | 2010-06-24 | — | — | US | disclosed |
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | MERCK PATENT GMBH (DE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099854-A1 | Use of pentadienoic acid derivatives for the treatment of hyperuricemia | XDH, URB2, ALOX12 | SCN9A 4035/4885HTR1A 877/4885HTR2B 1590/4885 |
| US-20100160410-A1 | USE OF PENTADIENOIC ACID DERIVATIVES FOR THE TREATMENT OF HYPERURICEMIA | XDH, URB2, ALOX12 | SCN9A 4035/4885HTR1A 877/4885HTR2B 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.